-
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Ju -
A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD
Liu S, Jia Z, Nie J, Liang Z, Xie J, Wang L, Zhang L, Wang X, Wang Y, Huang W. A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD. Cell Discov. 2022 Aug 17;8(1):81. doi: 10.1038/s41421-022-00443-w. Erratum in: Cell Discov. 2023 Dec 8;9(1):122. doi: 10.1038/s41421-023-00619-y. PMID: 35977939; PMCID: PMC9385086. -
Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence
Wen X, Zhang L, Liu Q, Xiao X, Huang W, Wang Y. Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence. Virol Sin. 2022 Aug;37(4):531-537. doi: 10.1016/j.virs.2022.04.015. Epub 2022 May 2. PMID: 35513270; PMCID: PMC9437608. -
Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses
Li Q, Zhang L, Liang Z, Wang N, Liu S, Li T, Yu Y, Cui Q, Wu X, Nie J, Wu J, Cui Z, Lu Q, Wang X, Huang W, Wang Y. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses. Signal Transduct Target Ther. 2022 Jul 27;7(1):256. doi: 10.1038/s41392-022-01123-7. PMID: 35896529; PMCID: PMC9328627. -
Animal models for COVID-19: advances, gaps and perspectives
Fan C, Wu Y, Rui X, Yang Y, Ling C, Liu S, Liu S, Wang Y. Animal models for COVID-19: advances, gaps and perspectives. Signal Transduct Target Ther. 2022 Jul 7;7(1):220. doi: 10.1038/s41392-022-01087-8. PMID: 35798699; PMCID: PMC9261903. -
Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies
Zhao MM, Zhu Y, Zhang L, Zhong G, Tai L, Liu S, Yin G, Lu J, He Q, Li MJ, Zhao RX, Wang H, Huang W, Fan C, Shuai L, Wen Z, Wang C, He X, Chen Q, Liu B, Xiong X, Bu Z, Wang Y, Sun F, Yang JK. Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies. Cell Discov. 2022 Jun 6;8(1):53. doi: 10.1038/s41421-022-00419-w. PMID: 35668062; PMCID: PMC9167920. -
Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD
Li Q, Zhang M, Liang Z, Zhang L, Wu X, Yang C, An Y, Tong J, Liu S, Li T, Cui Q, Nie J, Wu J, Huang W, Wang Y. Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD. MedComm (2020). 2022 Apr 9;3(2):e130. doi: 10.1002/mco2.130. PMID: 35434713; PMCID: PMC8994617. -
A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain
Chai M, Guo Y, Yang L, Li J, Liu S, Chen L, Shen Y, Yang Y, Wang Y, Xu L, Yu C. A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain. Brief Bioinform. 2022 May 13;23(3):bbac070. doi: 10.1093/bib/bbac070. PMID: 35362510. -
A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant
Liu Z, Chan JF, Zhou J, Wang M, Wang Q, Zhang G, Xu W, Chik KK, Zhang Y, Wang Y, Yuen KY, Lu L, Jiang S. A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. Cell Res. 2022 May;32(5):495-497. doi: 10.1038/s41422-022-00631-z. Epub 2022 Feb 24. PMID: 35210607; PMCID: PMC8866927. -
Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift
Li T, Cui Z, Jia Y, Liang Z, Nie J, Zhang L, Wang M, Li Q, Wu J, Xu N, Liu S, Li X, An Y, Han P, Zhang M, Li Y, Qu X, Wang Q, Huang W, Wang Y. Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. J Med Virol. 2022 May;94(5):2108-2125. doi: 10.1002/jmv.27596. Epub 2022 Jan 28. PMID: 35032057; PMCID: PMC9015629.